Introduction {#Sec1_24}
============

Hereditary breast cancer accounts for 5-10% of all BC cases \[[@CR1_24]\] and is characterized by dominant inheritance, premenopausal diagnosis, more severe course, bilaterality and frequent association with ovarian cancer (OC) \[[@CR2_24]\]. The identification of the two major hereditary breast/ovarian cancer genes, *BRCA1* (17q21, MIM\* 113705) in 1994 \[[@CR3_24]\] and *BRCA2* (13q14, MIM\* 600185) in 1995 \[[@CR4_24]\], led to a new era in the diagnosis of inherited high predisposition to breast and ovarian cancer \[[@CR5_24], [@CR6_24]\]. Breast-ovarian cancer (BOC)-causing mutations and other genetic variants are distributed along the entire coding and non-coding regions of *BRCA1* and *BRCA2*, and more than 3400 gene variants have been described in the *Breast Cancer Information Core* (BIC) \[[@CR7_24]\]. New variants continue to be detected worldwide, mostly in *BRCA1.*

The prevalences of *BRCA1/BRCA2* mutations in BOC patients with early onset (EO) and/or BOC family history (FH) appear to be similar across race/ethnicity, but there is evidence of important racial and/or geographic differences in the spectrum of *BRCA1/2* genetic variation, including pathogenic mutations and variants of uncertain significance. These differences may reflect population history and genetic drifts, and could have a significant impact on genetic counselling, genetic testing, and follow-up care \[[@CR8_24]\]. A typical example is provided by the case of Ashkenazi Jews, where three founder mutations: *BRCA1* c.66_67delAG *BRCA1* c.5263insC, and *BRCA2* c.5946delT account for most of familial breast-ovarian cancer \[[@CR9_24]\]. Founder *BRCA1* and *BRCA2* mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families \[[@CR10_24]\].

*BRCA1/2* mutation status in subsets of BOC patients selected for age, BOC family history and ethnicity has been scarcely investigated outside Europe and North America \[[@CR5_24], [@CR11_24]--[@CR15_24]\], with few reports for South America, where Native American founder effects and the complex multiracial demography of recent immigration are predicted to result in high genetic variation\[[@CR16_24]\]. Indeed, recent studies point to a role of Native American ancestry in *BRCA1/2* disease patterns in Central and Northern America \[[@CR17_24]--[@CR22_24]\]. Epidemiological data indicate that in Argentina BC incidence \[[@CR23_24]\] and mortality rates \[[@CR24_24]\] are among the highest in the world. The historical records and epidemiological and molecular studies point to variable degrees of admixture among European, mainly Spanish and Italian, and Native American components in more than 50% of the Argentinean population \[[@CR16_24], [@CR25_24]\]. Regarding autosomal evidence of admixture, the relative European, Native American, and West African genetic contributions to the Argentinean gene pool were estimated to be 67.55%, 25.9%, and 6.5%, respectively \[[@CR7_24]\].

Our study is the first report describing *BRCA1/BRCA2* gene variants in Argentinean BOC patients, and highlights a significant impact of novel mutations and genetic variants which may be regarded as putatively South American. On the other hand, we confirm the key role of founder *BRCA1* and *BRCA2* mutations in Argentinean Ashkenazi Jews.

Methods {#Sec2_24}
=======

The study includes 134 BOC probands selected either for age at cancer diagnosis or for family history (FH), according to the criteria listed in Table [1](#Tab1){ref-type="table"}. The patients selected for diagnosis within 40 years of age and no BOC FH (EO patients, any ethnicity) included 37 cases (21 with BC, 13 with OC, 3 with BOC; age range 12--40 years, mean age 31.0 ± 7.5 years). The FH patients (any age, 97 cases overall), selected based on the presence of at least two BOC-affected 1^st^ or 2^nd^ degree relatives, included 57 non-Ashkenazi patients (32 with BC, 18 with OC, 7 with BOC, age range 26--71 years, mean 44.6 ± 10.9 years), and 40 Ashkenazi patients (32 with BC, 6 with OC and 2 with BOC, age range: 32--64 years, mean age 47.1 ± 9.9 years) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The Ashkenazi subset was tested only for the panel of the three founder Ashkenazi mutations (c.66_67delAG (reported in BIC as 185delAG), and c.5263insC (in BIC as 5382insC) in *BRCA1* and c.5946delT (in BIC as 6174delT) in *BRCA2*); all the other cases were fully sequenced.Table 1**Inclusion criteria for the probands**Group (n)CriteriaNumber of probandsEO (37)Onset of cancer ≤40 years37Ashk-FH (40)Onset of cancer ≤40 years with family history12Onset of cancer \>40 years with family history28FH (57)Onset of cancer ≤40 years with family history31Onset of cancer \>40 years with family history26Total134**n**: total number of probands per group. **EO**: Early onset; **Ashk**: Ashkenazi; **FH**: Family history, defined as: at least 2 members of 1^st^ or 2^nd^ degree with breast and/or ovarian cancer.Table 2**Summary of the mutations detected**Total patients = 134 (group)Age at diagnosis (n)Family history***BRCA1***mutation (%)***BRCA2***mutation (%)% of mutated37 (EO)≤40 years (37)No4 (10.8)2 (5.4)16.240 (Ashk-FH)≤40 years (12)Yes3 (25.0)4 (33.3)58.3\>40 years (28)Yes6 (21.4)4 (14.3)35.757 (FH)≤40 years (31)Yes3 (9.7)3 (9.7)19.4\>40 years (26)Yes7 (26.9)2 (7.7)35.8**EO**: Early onset; **Ashk**: Ashkenazi; **FH**: Family History.Total coding *BRCA1-2* sequencing was performed for the patients in all groups except.the Ashkenazi patients which were tested for the panel of three mutations.**(n):** number of probands analyzed.

Blood samples were sent from the participating centers to the Laboratory HRDC of the Department of Biochemistry, University of Buenos Aires, and were also recruited at the Centro de Estudios Medicos e Investigaciones Clinicas (CEMIC). Study eligibility required signing an informed consent as a result of the routine procedures for genetic analysis. This study was approved by the Ethics Committee of the *Sociedad Argentina de Investigación Clínica.*

Genomic DNA was isolated using the QIAamp DNA blood purification kit (Qiagen, <http://www.qiagen.com>). The coding sequences and exon-intron boundaries of the *BRCA1-2* genes were analyzed by amplification using polymerase chain reaction (PCR) with alternative primers to avoid false results due to polymorphisms \[[@CR26_24], [@CR27_24]\], followed by direct sequencing of at least 55 amplicons, to ensure overlapping of the segments. Sequencing was performed using either an Applied Biosystems 3730xl DNA Analyzer or an Applied Biosystems ABI PRISM ® 310 Genetic Analyzer. Homozygosis (HO) was confirmed by alternative sequencing in exonic and/or intronic regions. The three Ashkenazi mutations were tested as described \[[@CR28_24]\]. Variants nomenclature follows the guidelines of the Human Genome Variation Society (HGVS). Tables provide lists including also the nomenclature of the Cancer Information Core Internet Website (BIC), April 2012.

Effects of the missense mutations that resulted not reported or recorded as clinically unknown (CU) in the BIC were predicted by virtual analyses of functional compatibility for aminoacid changes using two programs: Align-GVGD ([http://agvgd.iarc.fr/](http://agvgd.iarc.fr)) \[[@CR29_24]\] and SIFT ([http://sift.bii.a-star.edu.sg/](http://sift.bii.a-star.edu.sg)) \[[@CR30_24]\].

Results and discussion {#Sec3_24}
======================

We describe for the first time in Argentina the results of *BRCA1/BRCA2* germline analysis in 134 BOC probands selected either for diagnosis within 40 years of age (37 cases) or for FH (97 cases) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The latter included 40 Ashkenazi patients, tested only for the three founder Ashkenazi mutations \[[@CR28_24]\]. All the other cases were fully sequenced.

Overall 96 mutations and sequence variants, of which 53 in *BRCA1* and 43 in *BRCA2,* were identified in 94/134 patients analyzed. Mutation types, effects, carrier frequencies, worldwide occurrences and relevant references are listed in online Additional file [1](#MOESM1_24){ref-type="media"}: Tables S1 and Additional file [2](#MOESM2_24){ref-type="media"}: Table S2. The sequence variants were classified as pathogenic based on literature data and/or when predicted to truncate/inactivate the protein product.

Among the 53 sequence variants identified in *BRCA1* 15 are novel and 17 clinically unknown, 14 introduce a stop codon; 22 are missense substitutions (Additional file [1](#MOESM1_24){ref-type="media"}: Table S1). With regard to the 43 *BRCA2* mutations, 9 are novel, 17 clinically unknown, 6 introduce a stop codon; 15 are missense substitutions and one is predicted to result in an aberrant splice (Additional file [2](#MOESM2_24){ref-type="media"}: Table S2). The truncating mutations and the novel non-truncating variants predicted to affect the *BRCA1* and *BRCA2* gene products are described in Table [3](#Tab3){ref-type="table"}. Synonyms, intronic and polymorphic *BRCA1* and *BRCA2* variants ranged from 4 to 33 per individual patients and were detected in all the 94 fully-sequenced cases (Additional file [1](#MOESM1_24){ref-type="media"}: Table S1 and Additional file [2](#MOESM2_24){ref-type="media"}: Table S2). Notably, 34 variants are listed in BIC as of clinically unknown importance, and of these 14 were identified in unique patients (Additional file [1](#MOESM1_24){ref-type="media"}: Table S1 and Additional file [2](#MOESM2_24){ref-type="media"}: Table S2).Table 3***BRCA1/BRCA2*truncating mutations, novel and non-truncating variants affect the gene products*Exon**Codon**(HGVS) Protein level**(HGVS) DNA level**BIC DNA level**BIC Status**Carrier CODE**Index case Status (age)**Family history**Inclusion Criteria**Worldwide Occurrence**BRCA1***2E23VfsX16Stop cod39c.66_67delAG185delAGDAB54Br(37)BrAshk-EO-FHAshkenaziAB60Br(40)BrAshk-EO-AB77Ov (44)Br, OvFH Ashk-AB68Ov (44)Br, OvFH Ashk-AB76Br (49)BrFH Ashk-AB81Br (52)BrFH Ashk-AB87Ov (60)Br, OvFH Ashk-FH2E23KfsX18Stop cod40c.67insA186insADAB82Br (34)BrEO-FHNE/ME5C61Gp. Cys61Glyc.181 T \> G300 T \> CDAB75Br (49)BrFHE5R71Gp. Arg71Glyc.211A \> G330A \> GDAB64Br (43)BrFHE7E143Xp. Glu143Stopc.427 G \> T546 G \> TDAB46Br (33)Br, Ov, Pa, PrEO-FHE11S267KfsX19Stop cod285c.797_798delTT916delTTDAB36Br-Ov (46)BrFHC, L-A E, N-A**11K501Kfs30Stop cod530c.1502_1505delAATT1621delAATTNRAB20Br (32)NoEOArgentina**11R504VfsX28Stop cod531c.1510delC1629delCDAB40Br (30)BrEO-FHE**11E836GfsX2Stop cod837c.507_2508delAA2626delAANRAB67Br (50)Br**FH**Argentina11S896Vfs104Stop cod999c.2686delA2805delANRAB85Br (55)Br**FH**Argentina11Q910Xp. Gln910Stopc.2728 C \> T2847C \> TNRAB84Ov (55)Br, Ov, Co**FH**Argentina**11R1203Xp. Arg1203Stopc.3607C \> T3726C \> TDAB8Ov (25)NoEOC, L-A11E1210RfsX8Stop cod1218c.3627insA3746insADAB21Br-Ov (33)NoEOC, L-A, As**11S1253Xp. Ser1253Stopc.3758_3759delCT3877delCTNRAB17Br (31)NoEOArgentina**17T1677IfsX2Stop cod1678c.5030_5033delCTAA5149delCTAADAB79Br (51)\*Br, Ov, Pa, PrFHE20S1755PfsX75Stop cod1829c.5263insC5382insCDAB55Br (49)BrAshk-FH Ashk-EO-FHE, AshkenaziAB97Br (38)Br***BRCA2*9-Splice defectc.793 + 1delGIVS9 + 1delGNRAB99Br (31)BrEO-FHArgentina**11N955KfsX5Stop cod959c.2808_2811delACAA3036delACAADAB78Br (50)BrFHE, L-A11S1982RfsX22Stop cod2003c.5946delT6174delTDAB43Br (32)Br-maleAshk-EO-FHAshkenaziAB47Br (33)Br-maleAshk-EO-AB69Br/Ov (45)Br-maleFH Ashk-FHAB57Br (39)Br, Pa,Ashk-EO-AB71Br (46)Ov Pr,FH Ashk-AB74Br (48)BrFH Ashk-AB95Br (36)BrFH\
Ashk-AB96Br (60)BrEO-FH Ashk-FH11K1213Xp. Lys1213Stopc.6037A \> T6265A \> TDAB34Br (40)NoEOE11S1882Xp. Ser1882Stopc.5644C \> G5872C \> GDAB117Br (50)Br, PrFHE11Y1894XStop cod1894c.5909insA6137insADAB92Br (31)BrEO-FHE**14E2369EfsX23Stop cod2391c.7105insA7333insANRAB98Br (35)BrEO-FHArgentina**18D2723Hp. Asp2723Hisc.8169 G \> C8397 G \> CCUAB31Ov (38)NoEOE**D,** deleterious; **CU**, clinically unknown importance; **NR,** Not Reported in *Breast Information Core database(BIC)*[http://research.nhgri.nih.gov/bic/](http://research.nhgri.nih.gov/bic)**Global,** as defined in BIC or when reported in at least 3 continents ethnic groups in HapMap; **E**, European; **As**, Asian; **A-A** African-American; **L-A**, Latin American; **N-A**, Native-American; **A-C** America-Caucasian; **NE/ME**, Near Eastern/Middle Eastern;The DNA sequence numbering of BRCA1and BRCA2 sequence variants is based on recomendations of the Human Genome Variation Society (HGVS, translation initiation codon ATG = 1) *BRCA1:genomic sequence:L78833; RNA sequence: U14680; BRCA2 genomic sequence: NW_001838072; RNA sequence: NM_001838072*In bold, novel mutations not previously reported.

Overall, a total of 24 bona fide pathogenetic mutations, 16 in *BRCA1* and 8 in *BRCA2*, were detected in 38/134 cases (28.4%), including: a) 6/37 (16.2%) fully-sequenced patients in the group within 40 years of age; b) 15/57 (26.3%) fully-sequenced non-Ashkenazi FH patients; c) 17/40 (42.5%) Ashkenazi FH patients, analyzed for the three Ashkenazi mutations only (Table [2](#Tab2){ref-type="table"}). The pathogenetic mutations were more frequent in *BRCA1* (23/38, 60.5%) than in *BRCA2* (15/38, 39.5%), which is in agreement with literature data \[[@CR31_24]\].

The Ashkenazi-FH patients with age ≤40 years showed the highest frequency of pathogenetic *BRCA1* and *BRCA2* mutations, i.e., 58.3% (for *BRCA1* 16.7% in c.66_67delAG and 8.3% in c.5263insC and 33.3% for *BRCA2* c.5946delT), in agreement with literature frequencies \[[@CR28_24], [@CR32_24]\]. The detection rate of bona fide pathogenetic mutations in FH-negative probands selected for age within 40 years at diagnosis was 6/37 (16.2%). This falls within the 15-31% range reported in the literature for EO BOC with FH \[[@CR33_24]--[@CR36_24]\], but is in contrast with the lack of mutations reported in EO Chilean patients without FH \[[@CR37_24]\]. The published data on the South American population \[[@CR17_24], [@CR37_24], [@CR38_24]\] show lower rates of mutation detection, while in agreement with results from a study in the USA \[[@CR31_24]\] and a large study in high risk Hispanic family from USA \[[@CR39_24]\] and also with an study of Hispanic BOC from Colombia \[[@CR40_24]\]. Differences in mutation detection rates might reflect divergences in the criteria of proband selection and in the methods of analysis. In fact, the other South American \[[@CR37_24], [@CR38_24]\] reports were based on indirect mutation detection methods and not on full sequencing; in contrast, we used direct sequencing of all the amplicons along the *BRCA1* and *BRCA2* coding sequences and exon-intron boundaries.

It may be of interest to compare the deleterious mutation rates of the young patients with no FH (16.2%) and of the FH cases of similar age (within 40 years) in the non-Ashkenazi and Ashkenazi groups (Table [3](#Tab3){ref-type="table"}). Notably, a pathogenetic mutation was found in 6/31 (19.4%) non-Ashkenazi FH patients within 40 years of age (mean age 35.6 ± 4.8 years) and in 7/12 (58.3%) FH Ashkenazi cases within the same age cutoff (mean 35.6 ± 2.8 years). The recurrent Ashkenazi mutations were never detected in non-Ashkenazi probands. *BRCA1* c.66_67delAG, *BRCA1* c.5263insC and *BRCA2* c.5946delT were found in 7 (17.5%), 2 (5%) and 8 (20%) Ashkenazi probands, respectively. Interestingly, *BRCA2* c.5946delT was also found in a non-Ashkenazi FH patient who could recall a great grand mother of Ashkenazi origin. Conversely, only a non-Ashkenazi pathogenetic mutation (Asp2723His in *BRCA2*) was detected in one of 4 patients of Ashkenazi origin included in the subset selected for early diagnosis and no FH. This supports the full sequencing of EO Ashkenazi patients with no BOC FH.

With regard to disease association, the pathogenetic mutations in *BRCA1* occurred in 16/88 BC cases (18.2%), 5/24 OC cases (20.8%) and 2/22 BOC cases (9.1%), those in *BRCA2* in 13/88 BC cases (14.8%), 1/24 OC cases (4.2%) and 1/22 BOC cases (4.5%). As expected, OC was more frequent in *BRCA1* carriers (21.7% vs 6.7%), and BC in *BRCA2* carriers (86.6% vs 65.2%) \[[@CR30_24]\].

Seven pathogenic mutations (18.4% of all the mutations detected) were putatively novel: 5 in *BRCA1* (21.7% for this gene), all with frameshifts generating stop codons in exon 11, and 2 *in BRCA2 (13*.3% for this gene), one with a frameshift at nt 2369, exon 14 (c7333 insA), the other (c.793 + 1delG) affecting the donor splicing site nucleotide at IVS + 1 delG in intron 9 (Table [3](#Tab3){ref-type="table"}).

The frequency of the common non-pathogenic variants and synonyms was in agreement with that reported in the BIC. The mutations reported in BIC as CU that we detected in multiple patients as homozygous (in parenthesis number of cases) and/or in association with deleterious mutations, such as p. Gln356Arg, IVS7 + 36 C \> T, IVS7 + 41 C \> T, IVS14-63 C \> G, and IVS18 + 66 G \> A in *BRCA1* and p. Val2171Val (9), p. Ala2466Val (4), IVS8 + 56 C \> T, IVS9 + 65delT, IVS10 + 12delT, and IVS11 + 80delTTAA (1) in *BRCA2* most probably represent non-pathogenic variants. Furthermore, based on prediction programs, homozygous status, detection in multiple unrelated patients and/or association with pathogenic mutations, 10 variants found in the present study and not reported in the BIC can be considered non pathogenic. These include p. Val122Asp, p. Gln139Lys, IVS7 + 38 T \> C, IVS7 + 49 del 15 bp, in *BRCA1* and c\*110 A \> C at 3\'UTR in *BRCA2* (two other novel *BRCA2* variants, i.e., IVS4 + 246 G \> C and IVS4 + 364delT, located far from the end of the exon 4 are reported here only as heterozygosity markers).

Five of the 28 missense variants (Table [4](#Tab4){ref-type="table"}) (i.e., p. Arg7Cys, p. Cys61Gly, p. Arg71Gly, p. Tyr179Cys, and p. Met1652Thr in *BRCA1*, p. Asp2723His in *BRCA2*) were predicted to have an impact on protein structure upon evaluation by SIFT and GVGD (Table [4](#Tab4){ref-type="table"}). *BRCA1* p. Arg7Cys, differently from the other non-conservative variants, has a rather low prediction score and was found in two cases. The high prediction values for *BRCA1* p. Cys61Gly and *BRCA1* p. Arg71gly agree with their previously reported pathogenicity \[[@CR41_24], [@CR42_24]\] (Table [4](#Tab4){ref-type="table"}). Few reported data are available for *BRCA2* p. Asp2723His \[[@CR43_24]\]. *BRCA1* p. Met1652Thr, located in the BRCT tandem repeat region is predicted to result in a large volume change in rigid neighbourhood \[[@CR44_24]\] but structural and functional assays show normal peptide binding specificity and transcriptional activity \[[@CR45_24]\]. Tyr179Cys is also located in a highly conserved region and is listed as clinically importance unknown (CU) in BIC. Notably BRCA1 Tyr179Cys co-occurred with two other missense mutations, i.e., Phe486Leu and Asn550His, in an FH patient affected with pagetoid BC (AB80). These 3 mutations, already reported to occur together, may constitute a rare haplotype \[[@CR46_24]\] \[brca.iarc.fr/LOVD\].Table 4***BRCA1/2*missense variants identified in 94 (non Askenazi) Argentinean breast/ovarian cancer cases*[HGVS :]{.ul}**Protein: DNA**BIC: Status**N° Carrier (%)**Co-occurrence with deleterious**[Prediction]{.ul}**SIFT GVGD grade**refSNP**BRCA1*p. Arg7Cysc.19C \> TCU2(1.1)**-**NTC15**rs144792613**p. Cys61Glyc.181 T \> GD1 (1.1)**-**NTC65**-**p. Arg71Glyc.211A \> GD1 (1.1)**-**NTC65**-p. Val122Aspc.365 T \> ANR5 (5.3)*BRCA2*TC0-p. Gln139Lysc.415C \> ANR6 (6.3)-TC0-**p. Tyr179Cysc.536A \> GCU1 (1.1)***BRCA1* \[[@CR30_24]\] (AB80)**NTC35**rs56187033p. Gln356Argc.1067A \> GCU10 (10.6)*BRCA1/BRCA2\#*TC0rs1799950p. Phe486Leuc.1456 T \> CCU1 (1.1)*BRCA1* \[[@CR30_24]\] (AB80)TC0rs55906931p. Val525Ilec.1573 G \> ACU1 (1.1)-TC0rs80357273p. Asn550Hisc.1648A \> CCU1 (1.1)*BRCA1* \[[@CR30_24]\] (AB80)NTC0rs56012641p. Asp693Asnc.2077 G \> ACN8 (8.5)*BRCA1*TC0rs4986850p. Pro871Leuc.2612C \> TCN29 (30.9)*BRCA1/BRCA2\#*TC0rs799917p. Lys898Gluc.2692A \> GCU1 (1.1)*BRCA2*TC0rs80357420p. Met1008Ilec.3024 G \> ACU1 (1.1)*BRCA1* \[[@CR30_24]\]TC0rs1800704p. Glu1038Glyc.3113 G \> ACN33 (35.1)*BRCA1/BRCA2\#*TC0rs16941p. Ser1040Asnc.3119 G \> ACU1 (1.1)*BRCA1* \[[@CR31_24]\]TC0rs4986852p. Asp1131Gluc.3393C \> GNR1 (1.1)*BRCA2*TC0-p. Lys1183Argc.3548A \> GCN34 (36.2)*BRCA1/BRCA2\#*TC0rs16942p. Ile1275Valc.3823A \> GCU8 (8.5)-TC0rs80357280p. Glu1586Glyc.4757A \> GNR1 (1.1)-NTC0-p. Ser1613Glyc.4837A \> GCN33 (35.1)*BRCA1/BRCA\#*TC0rs1799966**p. Met1652Thrc.4955 T \> CCU1 (1.1)**-**NTC25**rs80356968***BRCA2***p. Tyr42Cysc.125A \> GCU(BIC)1 (1.1)-TC0rs4987046p. Asn289Hisc.865A \> CCN5 (5.3)*BRCA2*NTC0rs766173p. His372Asnc.1114C \> ACN24 (4.2)*BRCA1/BRCA2\#*TC0rs144848p. Arg858Ilec.2578 G \> TNR1 (1.1)*BRCA2*TC0-p. Asn991Aspc.2971A \> GCN4 (4.2)*BRCA2*TC0rs1799944p.Q1063Kc.3187C \> ANR1 (1.1)-TC0-p. Asp1420Tyrc.4258 G \> ACN1 (1.1)*BRCA2* \[[@CR32_24]\]TC0rs28897727p. Met1915Thrc.5744 T \> CCU1 (1.1)-TC0rs4987117p. Ser2098Phec.6749C \> TCU1 (1.1)-TC0rs80358867p. Arg2108Hisc.6323 G \> ACU1.(1.1)-TC0rs35029074p. Ala2466Valc.7397C \> TCU37 (39.4)*BRCA1*/*BRCA2*\#NTC0rs169547p. Asn2486Lysc.7919 T \> GNR1(1.1)-TC0-p. Ile2490Thrc.7469 T \> CCU6 (6.3)-NTC0rs11571707**p. Asp2723Hisc.8167 G \> CCU1 (1.1)**-**NTC65**rs41293511p. Ile3412Valc.10690A \> GCU3 (3.2)-TC0rs1801426**NR**, Not Reported **CU**, Clinically Unknown**; CN,** clinically not important, in *Breast Information Core database* (BIC), [http://research.nhgri.nih.gov/bic/](http://research.nhgri.nih.gov/bic);In bold missense predict deleterious; **NT,** Not Tolerated; **T**, Tolerated; Align-**GVGD grade** between C0 and C65; **Co-occurrence: \#** two or more patients.

In agreement with the complex population history of Argentina, the *BRCA1/2* mutations detected in this BOC series were associated with diverse geographic/ethnic backgrounds (Figure [1](#Fig1){ref-type="fig"} and online Additional file [1](#MOESM1_24){ref-type="media"}: Table S1 and Additional file [2](#MOESM2_24){ref-type="media"}: Table S2). Of the 96 detected variants, 25 (26%) are not reported in the BIC, in HapMap \[[@CR47_24]\] and in the current literature, and are thus putatively unique for Argentina, 17 (17.7%) were reported worldwide (at least 3 continents), 4 (4.2%) were reported only in Latin-America. The remaining variants comprise mutations previously detected in Europe, Asia and North America. (Additional file [1](#MOESM1_24){ref-type="media"}: Table S1 and Additional file [2](#MOESM2_24){ref-type="media"}: Table S2). The putative Latin American variants include p. Ile2490Thr in *BRCA2,* a modestly penetrant variant that might contribute to sporadic breast cancer risk, listed as CU in the BIC, originally described in a Caribbean patient \[[@CR48_24]\] and reported almost 100 times in the BIC, frequently associated to Latin American probands. In this line, several novel variants were previously observed in Argentina in genes related to other hereditary syndromes and might be regarded as putatively regional or influenced by founding events, \[[@CR49_24]--[@CR51_24]\]. In the present case series this mutation recurred in six cases (Table [4](#Tab4){ref-type="table"}, Figure [1](#Fig1){ref-type="fig"})Figure 1**Worldwide occurrence of 96 BRCA1/2 variants detected in 94 non-Ashkenazi Argentinean BOC patients.Global**, as defined in BIC or when reported in at least 3 continents in HapMap or in references; **A**, African; **AA**, African American; **AC**, American Caucasian; **As**, Asian; **Ashk**, Ashkenazi; **E**, European; **LA**, Latin American; **NA**, Native American; **NE/ME**, Near Eastern/Middle Eastern; **ND**, not determined.

Two other mutations related to South American ethnicity deserve mention: 1) *BRCA1* IVS7 + 37 del14bp(TTTTCTTTTTTTTT), not listed in BIC but found in 10/42 families from Uruguay (including one with a pathogenetic mutation in *BRCA2*) \[[@CR38_24]\], and in a patient from Chile \[[@CR37_24]\]; and 2) *BRCA2* IVS16-14 T \> C, reported in a patient from Uruguay \[[@CR38_24]\] and detected in 31 of our patients (including 4 with identified pathogenic mutations).

Conclusions {#Sec4_24}
===========

The present study is the first reporting the spectrum of *BRCA1* and *BRCA2* mutations in an Argentinean BOC series, based on the analysis of the coding sequences and exon-intron boundaries of both genes. Given that the rates of BC incidence and mortality in Argentina are among the highest in the world \[[@CR23_24], [@CR24_24]\], a better understanding of the impact of *BRCA1/BRCA2*-related disease in Argentinean BOC patients is important for the implementation of prevention and/or early detection strategies. In our case series selected for early diagnosis with no FH or for FH independently of age at diagnosis, the overall detection rate of bona fide pathogenetic mutations was quite high (38/134, 28.3%). This could rise to 35.8% (48/134) including the missense mutations suspected to confer increasing risk of breast cancer.

Although global and European sequence variants contribute to near 45% of the detected *BRCA1/2* variation, the significant fraction of new variants putatively unique for Argentina detected in the present study might suggest the presence of a Native American genetic component, not yet genetically characterized, that it in recent centuries has come to admixture with alleles mostly of European origin.
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